SITC Cancer Immunotherapy Guidelines – Cutaneous Melanoma Webinar on July 30 Join SITC experts to discuss immunotherapy treatment standards for melanoma on the recently updated clinical guidelines manuscript in a free webinar at 6 p.m. ET on July 30.
Learn about immunology principles in immunotherapy of cancer at the SITC Primer on Tumor Immunology and Cancer Immunotherapy™, part of our Pre-Conference Programs, on Nov. 8, 2018.
"An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0"
The Society for Immunotherapy of Cancer’s new online activity explains cancer immunotherapy and the immune system to patients.
SITC 2018 registration is now open to the public. Also, submit an abstract to the 33rd Annual Meeting or presentation application to the Immune Escape program!
See members discuss the benefits of a SITC membership in this new video.
SITC members who purchase Cancer Immunotherapy Principles and Practice receive a 20 percent discount and free shipping with a promo code.*
*Available only when ordering from Demos Medical Publishing. Cannot be combined with any other offers.
Explore resources and educational opportunities for cancer patients and those who advocate for them.
Track the latest advancements and educational opportunities in cancer immunotherapy and immunology.
Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.
At the outset it would seem that a deactivation of immune system stands be antithetical to the very purpose of immunotherapy-based approach whereby a healthy uncompromising immune systems is need as a platform for any effective CART-1 PD-CART or PD -PDl1 ...
At the outset it would seem that a deactivation of immune system stands be antithetical to the very purpose of immunotherapy-based approach whereby a healthy uncompromising immune systems is need as a platform for any effective CART-1 PD-CART or PD ...
Hello Dr. Ramakrishna, The answer is not know yet. There are many trials (listed below) aimed at this indication. None that I know of yet are combining targeted therapy (FLT3 inhibitor) with immune therapy, but I am sure there will be some coming ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com